Stonebridge Financial Group LLC Purchases Shares of 36,054 Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Stonebridge Financial Group LLC acquired a new position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 36,054 shares of the company’s stock, valued at approximately $286,000.

A number of other large investors have also recently made changes to their positions in AMRX. JPMorgan Chase & Co. raised its stake in Amneal Pharmaceuticals by 149.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,297,094 shares of the company’s stock worth $10,792,000 after acquiring an additional 777,568 shares during the period. Barclays PLC increased its stake in shares of Amneal Pharmaceuticals by 134.1% in the third quarter. Barclays PLC now owns 296,384 shares of the company’s stock worth $2,466,000 after purchasing an additional 169,756 shares in the last quarter. State Street Corp increased its stake in shares of Amneal Pharmaceuticals by 3.8% in the third quarter. State Street Corp now owns 3,514,721 shares of the company’s stock worth $29,242,000 after purchasing an additional 127,753 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in shares of Amneal Pharmaceuticals during the 4th quarter valued at $520,000. Finally, Geode Capital Management LLC lifted its stake in shares of Amneal Pharmaceuticals by 11.1% during the 3rd quarter. Geode Capital Management LLC now owns 3,786,671 shares of the company’s stock valued at $31,511,000 after buying an additional 378,136 shares in the last quarter. 31.82% of the stock is owned by hedge funds and other institutional investors.

Amneal Pharmaceuticals Stock Performance

AMRX opened at $7.96 on Wednesday. The stock has a market capitalization of $2.47 billion, a price-to-earnings ratio of -11.71 and a beta of 1.10. The company has a fifty day moving average of $8.12 and a 200 day moving average of $8.25. Amneal Pharmaceuticals, Inc. has a fifty-two week low of $5.01 and a fifty-two week high of $9.48.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. Piper Sandler increased their price target on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the stock an “overweight” rating in a research note on Monday, November 11th. StockNews.com lowered Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, December 19th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $10.00.

Insider Buying and Selling at Amneal Pharmaceuticals

In related news, Director Gautam Patel sold 17,410 shares of the business’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $8.01, for a total value of $139,454.10. Following the sale, the director now owns 2,031,476 shares in the company, valued at approximately $16,272,122.76. The trade was a 0.85 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Jason B. Daly sold 43,657 shares of the stock in a transaction on Friday, November 15th. The shares were sold at an average price of $8.61, for a total transaction of $375,886.77. Following the transaction, the senior vice president now owns 13,665 shares of the company’s stock, valued at $117,655.65. This trade represents a 76.16 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 203,657 shares of company stock valued at $1,667,887 in the last 90 days. Insiders own 26.56% of the company’s stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.